Actively Recruiting
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Led by University of Wisconsin, Madison · Updated on 2026-03-19
10
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
CONDITIONS
Official Title
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor
You will not qualify if you...
- Unable to lie flat during or tolerate PET/CT or SPECT/CT scans
- Known incompatibility or allergy to CT, SPECT, or PET scans
- Unlikely to comply with study procedures and judged unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Wisconsin - Madison
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
R
Radiology Studies
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here